注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Calliditas Therapeutics AB(原名:Pharmalink AB)是一家瑞典的專業製藥公司。該公司從事開發和商業化其候選藥品Nefecon,用於治療腎臟炎(免疫球蛋白A腎病)患者。這類患者面臨發展為腎功能衰竭的風險。Nefecon源自TARGIT技術,這種技術可以保護含有活性藥物的膠囊,使其完整地穿過腸胃,最終到達小腸下端並釋放所含物質。Nefeco結合了時間間隔與特定區域內活性物質布地奈德的集中釋放。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Elmar J. Schnee | 63 | 2019 | Independent Chairman |
Vladimir Tesar | - | - | Member of Scientific Advisory Board |
Hérnan Trimarchi | - | - | Member of Scientific Advisory Board |
Brad H. Rovin | - | - | Member of Scientific Advisory Board |
Jürgen Floege | - | - | Member of Scientific Advisory Board |
Jonathan Barratt | - | - | Member of Scientific Advisory Board |
Richard Lafayette | - | - | Member of Scientific Advisory Board |
Hilde Furberg | 65 | 2014 | Independent Non-Executive Director |
Elisabeth Bjork | 62 | 2022 | Independent Director |
Hong Zhang | - | - | Member of Scientific Advisory Board |
Heather N. Reich | - | - | Member of Scientific Advisory Board |
Diane L. Parks | 72 | 2019 | Independent Non-Executive Director |
Henrik Stenqvist | 57 | 2022 | Independent Non-Executive Director |
Frederick W. Driscoll | 73 | 2023 | Independent Non-Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核